Latest news

• FDA knocks back DBV’s peanut allergy therapy once again

  drug. Like Palforzia, the rationale for Viaskin Peanut is to expose people with peanut allergy to small amounts of antigen over time to encourage the immune system to develop tolerance. ... Analysts at Baird have suggested that with a weaker clinical

• Aimmune’s Palforzia is first peanut allergy drug cleared in US

  When used in conjunction with peanut avoidance, Palforzia provides an FDA-approved treatment option to help reduce the risk of these allergic reactions in children with peanut allergy,” added Marks. ... California biotech Aimmune has been in a race to

• Aimmune gets FDA panel backing for peanut allergy therapy

  Peanut allergies are the leading cause of death from food-induced allergic reactions in the US. ... DBV was forced to withdraw the US marketing application for its Viaskin Peanut patch product last December after the FDA expressed concerns about

• DBV refiles peanut allergy immunotherapy in the US

  Follows initial manufacturing concerns. DBV Technologies was hit hard a few months back when it was forced to pull its FDA filing for peanut allergy therapy Viaskin Peanut. ... This is an important milestone for DBV, as we are one step closer towards

• Aimmune wins over ICER for peanut allergy product

  for the 1.6m people with peanut allergy in the US, and presented its case at an ICER meeting yesterday. ... Aimmune is currently leading the race to bring a peanut allergy therapy to market, after its main rival DBV Technologies decided to withdraw the